STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCTC
  4. [8-K] Catalyst Crew Technologies Corp. Reports Material Event

Catalyst Crew Technologies (CCTC) consolidates AI healthcare IP into Venezuelan subsidiary

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Catalyst Crew Technologies Corp. entered an Asset Purchase Agreement on February 17, 2026 with its CEO, Kevin Rodan Levy, to acquire assets for an artificial intelligence-enabled healthcare analytics platform, including CardioAI, PulmoAI, and NeuroAI intellectual property registered in Venezuela.

On March 23, 2026, the company acquired 100% of the shares of Inversiones Long 33, C.A., which became a wholly-owned Venezuelan subsidiary intended as its local operating entity within a broader Latin American strategy. On April 7, 2026, certain previously acquired intellectual property was assigned to this subsidiary as an internal reorganization step with no additional consideration.

The company also highlighted multiple press releases between March 23 and April 13, 2026 describing its operating structure, intellectual property assignments, and the introduction of its CardioAI, PulmoAI, and NeuroAI platforms.

Positive

  • None.

Negative

  • None.

Insights

Catalyst Crew consolidates Venezuelan AI healthcare assets into a wholly-owned subsidiary.

Catalyst Crew Technologies Corp. has formalized ownership of its artificial intelligence-enabled healthcare portfolio by purchasing assets from CEO Kevin Rodan Levy and acquiring 100% of Inversiones Long 33, C.A., now a wholly-owned Venezuelan subsidiary. CardioAI, PulmoAI, and NeuroAI intellectual property is central to this structure.

The subsequent assignment of these rights from the parent to the subsidiary on April 7, 2026 is framed as an internal reorganization with no additional consideration. This concentrates operating and IP risk in a Venezuelan entity, which may carry country-specific regulatory and operational considerations not detailed here.

The company’s press releases between March 23 and April 13, 2026 emphasize its Latin American operating structure and AI platforms. Future disclosures may clarify commercialization progress, revenue contribution, and how this structure supports the broader regional strategy.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.01 Completion of Acquisition or Disposition of Assets Financial
The company completed a significant acquisition or sale of business assets.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Asset Purchase Agreement date February 17, 2026 Date CCTC agreed to acquire AI healthcare assets from CEO
Subsidiary share acquisition date March 23, 2026 Date CCTC acquired 100% of Inversiones Long 33, C.A.
Ownership of Inversiones Long 33, C.A. 100% of issued and outstanding shares Inversiones Long 33, C.A. became a wholly-owned subsidiary
IP assignment date April 7, 2026 Date certain AI-related IP was assigned to the subsidiary
CardioAI registration number VEN-SAPI-2025-005287 Patent registration for CardioAI in Venezuela
PulmoAI registration number VEN-SAPI-2025-009419 Patent registration for PulmoAI in Venezuela
NeuroAI registration number VEN-SAPI-2024-033782 Patent registration for NeuroAI in Venezuela
8-K signature date April 13, 2026 Date the report was signed by the CEO
Asset Purchase Agreement financial
"entered into an Asset Purchase Agreement (the “APA”) with its Chief Executive Officer"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
Share Assignment Agreement financial
"entered into a Share Assignment Agreement with Seller pursuant to which the Company acquired"
Intellectual Property Assignment Agreement financial
"Seller entered into an Intellectual Property Assignment Agreement with the Subsidiary"
wholly-owned subsidiary financial
"Inversiones Long 33, C.A. is a wholly-owned subsidiary of the Company"
A wholly-owned subsidiary is a company whose entire ownership is held by another company, called the parent, so the parent controls all shares, board appointments and major decisions. For investors this matters because the subsidiary’s profits, losses, assets and liabilities are treated as part of the parent’s financial picture, affecting valuation and risk exposure — imagine a parent owning a single storefront outright and consolidating its receipts and bills into the parent’s books.
Regulation FD Disclosure regulatory
"Item 7.01 – Regulation FD Disclosure On March 23, 2026, March 26, 2026"
Understanding 8-K Material Events →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 13, 2026 (February 17, 2026)

 

CATALYST CREW TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)  

 

Nevada

 

000-52543

 

26-3670551

(State or other jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Av. Rómulo Gallegos con Av. Las Palmas

Edif. Torre Gerencial Los Andes

Caracas 1071, Venezuela

(Address of principal executive offices, including zip code.)

 

+1 787 476 2350

(Telephone number, including area code)

 

____________________________________________

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

Catalyst Crew Technologies Corp.

Form 8-K

Current Report

 

Item 1.01 Entry into a Material Definitive Agreement

 

On February 17, 2026, Catalyst Crew Technologies Corp. (the “Company”) entered into an Asset Purchase Agreement (the “APA”) with its Chief Executive Officer, Kevin Rodan Levy (the “Seller”), pursuant to which the Company acquired certain assets, including intellectual property relating to an artificial intelligence-enabled healthcare analytics platform. The closing of the transactions contemplated by the APA occurred on or about February 20, 2026. The acquired assets include, among other things, proprietary software, machine learning models, datasets, and intellectual property, including certain patent registrations in Venezuela associated with the Company’s CardioAI, PulmoAI, and NeuroAI technologies.

 

On March 23, 2026, the Company entered into a Share Assignment Agreement with Seller pursuant to which the Company acquired one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A., a corporation organized under the laws of the Bolivarian Republic of Venezuela (the “Subsidiary”).

 

On April 7, 2026, the Seller entered into an Intellectual Property Assignment Agreement with the Subsidiary, pursuant to which certain intellectual property rights previously acquired by the Company pursuant to the APA were formally assigned to the Subsidiary, including:

 

 

·

CardioAI – Registration No. VEN-SAPI-2025-005287

 

·

PulmoAI – Registration No. VEN-SAPI-2025-009419

 

·

NeuroAI – Registration No. VEN-SAPI-2024-033782

 

The assignment of intellectual property to the Subsidiary was an internal reorganization step intended to align the Company’s operating structure in Venezuela. The Company previously acquired such intellectual property pursuant to the APA, and the assignment to the Subsidiary did not represent a new acquisition of intellectual property. No additional consideration was paid in connection with the assignment.

 

The foregoing descriptions of the Asset Purchase Agreement, Share Assignment Agreement, and Intellectual Property Assignment Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are filed or will be filed as exhibits.

 

Item 2.01 – Completion of Acquisition or Disposition of Assets

 

On March 23, 2026, the Company completed the acquisition of one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A. pursuant to a Share Assignment Agreement with Kevin Rodan Levy. As a result of the foregoing, Inversiones Long 33, C.A. is a wholly-owned subsidiary of the Company. The Subsidiary was previously formed and is intended to serve as the Company’s operating entity in Venezuela and as part of its broader Latin American strategy.

 

Item 7.01 – Regulation FD Disclosure

 

On March 23, 2026, March 26, 2026, April 7, 2026, April 9, 2026, and April 13, 2026, the Company issued press releases announcing (i) the establishment of its operating structure, (ii) the assignment of intellectual property, and (iii) the introduction of its CardioAI, PulmoAI, and NeuroAI platforms, which form part of the Company’s artificial intelligence-enabled healthcare technology portfolio.

 

Copies of such press releases are available on publicly accessible platforms, including Yahoo Finance.

 

The information contained in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

 

Item 9.01 – Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.

 

Description

10.1

 

Asset Purchase Agreement, dated February 17, 2026, by and between Kevin Rodan Levy and Catalyst Crew Technologies Corp.*

10.2

 

Share Assignment Agreement, dated March 23, 2026, by and between Kevin Rodan Levy and Catalyst Crew Technologies Corp.

10.3

 

Intellectual Property Assignment Agreement, dated April 7, 2026, by and between Kevin Rodan Levy and Inversiones Long 33, C.A.

104 

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

                *Previously filed as part of the Company’s Current Report on Form 8-K as filed with the SEC in February 25, 2026.

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 13, 2026

 

 CATALYST CREW TECHNOLOGIES CORP.
    
By:/s/ Kevin Rodan Levy

 

 

Kevin Rodan Levy 
  Chief Executive Officer and Director 

 

 
3

 

Source: View Original Filing on SEC EDGAR

FAQ

What major agreements did Catalyst Crew Technologies (CCTC) enter into in early 2026?

Catalyst Crew Technologies entered an Asset Purchase Agreement on February 17, 2026 and a Share Assignment Agreement on March 23, 2026. These covered acquisition of AI healthcare assets and 100% of Inversiones Long 33, C.A., formalizing its Venezuelan operating and intellectual property structure.

What assets did CCTC acquire from its CEO Kevin Rodan Levy?

CCTC acquired assets tied to an artificial intelligence-enabled healthcare analytics platform from CEO Kevin Rodan Levy. These include proprietary software, machine learning models, datasets, and Venezuelan patent registrations related to CardioAI, PulmoAI, and NeuroAI technologies supporting its healthcare technology portfolio.

Why did CCTC assign intellectual property to its Venezuelan subsidiary?

On April 7, 2026, certain intellectual property previously acquired by CCTC was assigned to Inversiones Long 33, C.A. The company describes this as an internal reorganization step to align its Venezuelan operating structure, with no additional consideration or new intellectual property acquisition involved.

Which AI healthcare platforms has CCTC highlighted in its recent disclosures?

CCTC has highlighted three artificial intelligence-enabled healthcare platforms: CardioAI, PulmoAI, and NeuroAI. These platforms are supported by Venezuelan patent registrations and were featured in press releases on March 23, March 26, April 7, April 9, and April 13, 2026 as part of its technology portfolio.

Filing Exhibits & Attachments

7 documents

Agreements & Contracts

Other Documents